Market Scorecard
Market Pathways Scorecard: FDA Q1 Trends
A graphic look at Q1 FDA actions amid workforce cuts and disruptions by the Trump administration.
Welcome to MyStrategist
Quickly uncover the breadth and depth of the editorial offerings found only in MedTech Strategist and Market Pathways – the medtech industry’s leading sources of global business, regulatory, and reimbursement analysis and intelligence on an all-in-one, digital platform. Think Strategically. Subscribe Today
Start a free trial and unlock 5-days of exclusive subscriber-only access to MedTech Strategist & Market Pathways
Start Trial
MedTech Innovator Presents
Dialed In: Start-Ups Overcome Drug Delivery Drawbacks
Three MTI cohort companies’ devices show promise for more focused and effective drug delivery, among other applications.
Don't Just Advertise... Strategize!
Advertise with MedTech Strategist and be seen by medtech's most influential executives.
Learn More
Pathways' Picks
Pathways' Pick of the Week: Trump Era’s First De Novo
FDA authorized its first De Novo in the Trump era. Excerpted from Pathways’ Picks March 26: MDR Reform Input Streams In, Makary Confirmed at FDA, and More.